Effects of pioglitazone and metformin on β-cell function in nondiabetic subjects at high risk for type 2 diabetes

被引:20
|
作者
Rasouli, Neda
Kern, Philip A.
Reece, E. Albert
Elbein, Steven C.
机构
[1] Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Med, Div Endocrinol, Little Rock, AR USA
[3] Univ Arkansas Med Sci, Coll Med, Dept Obstet & Gynecol, Little Rock, AR USA
关键词
insulin sensitizer; prediabetes;
D O I
10.1152/ajpendo.00221.2006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of pioglitazone and metformin on beta-cell function in nondiabetic subjects at high risk for type 2 diabetes. Am J Physiol Endocrinol Metab 292:E359-E365, 2007. First published September 12, 2006;doi:10.1152/ajpendo.00221.2006. Thiazolidinediones (TZDs) and metformin decreased the incidence of diabetes in subjects at risk for developing diabetes and improved peripheral or hepatic insulin sensitivity, respectively. Whether they also directly improved beta-cell function is not clear. In vitro studies showed improved beta-cell function in response to TZDs and metformin; however, the effects of TZDs or metformin on beta-cell function in humans are still uncertain. We hypothesized that both TZDs and metformin directly affect beta-cell function. We evaluated beta-cell function and insulin sensitivity (SI) in subjects with impaired glucose tolerance or a history of gestational diabetes using oral and intravenous glucose tolerance tests in addition to the glucose-potentiated arginine stimulation test. In contrast to metformin, pioglitazone improved S-I, glucose tolerance, and insulin-independent glucose disposal [glucose effectiveness (SG)]. Neither pioglitazone nor metformin significantly improved beta-cell compensation for insulin resistance [disposition index (DI)], but the change in DI significantly correlated with baseline SI. Insulin secretion in response to arginine at maximally potentiating glucose levels (AIR(max)) tended to increase after metformin and to decrease after pioglitazone; however, when adjusted for SI, the changes were not significant. Our results demonstrate that, in nondiabetic subjects at risk for diabetes, pioglitazone, but not metformin, significantly improved glucose tolerance by improving SI and SG. We did not find any evidence that either pioglitazone or metformin improved beta-cell function. Improved beta-cell compensation was observed primarily in the subgroup of subjects that had the lowest SI at baseline.
引用
收藏
页码:E359 / E365
页数:7
相关论文
共 50 条
  • [21] Combining pioglitazone with a sulphonylurea or metformin in the management of type 2 diabetes
    Hanefeld, M
    Göke, B
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 : S256 - S266
  • [22] Effect of Alogliptin Combined with Pioglitazone on β-Cell Function and Insulin Resistance in Metformin-Treated Patients with Type 2 Diabetes
    Defronzo, Ralph A.
    Burant, Charles F.
    Fleck, Penny
    Wilson, Craig
    Mekki, Qais
    Pratley, Richard
    DIABETES, 2009, 58 : A519 - A519
  • [23] Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared With Pioglitazone and Metformin Monotherapy in Patients With Type 2 Diabetes
    Perez, Alfonso
    Jacks, Randal
    Arora, Vipin
    Spanheimer, Robert
    JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (12): : 973 - 982
  • [24] Effects of insulin administration on beta-cell function in subjects at high risk for type I diabetes mellitus
    RodriguezVillar, C
    Conget, I
    GonzalezClemente, JM
    Vidal, J
    Navarro, P
    Casamitjana, R
    Gomis, R
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (07): : 873 - 875
  • [25] Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes
    Xiao, C. -C.
    Ren, A.
    Yang, J.
    Ye, S. -D.
    Xing, X. -N.
    Li, S. -M.
    Chen, C.
    Chen, R. -P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2015, 19 (06) : 963 - 970
  • [26] Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects
    Standl, E
    DIABETES & METABOLISM, 2003, 29 (04) : S121 - S122
  • [27] Effects of Pioglitazone and Metformin Combination Therapy on High-Molecular-Weight Adiponectin Compared With Metformin Monotherapy in Type 2 Diabetes Mellitus Patients
    Matsushita, Takaya
    Kaji, Akino
    Kaji, Kuniaki
    Takahashi, Eri
    Usui, Takahiro
    Asahi, Nobuteru
    Sato, Tomoya
    Ohono, Atushi
    Ueki, Akio
    DIABETES, 2012, 61 : A626 - A626
  • [28] Effects of the addition of pioglitazone on insulin resistance, beta cell function and proinsulin/insulin ratio in patients with type 2 diabetes inadequately controlled on metformin and a sulphonylurea
    Halimi, S.
    Charpentier, G.
    DIABETOLOGIA, 2006, 49 : 491 - 492
  • [29] Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes
    Chalmers, J.
    Hunter, J. E.
    Robertson, S. J.
    Baird, J.
    Martin, M.
    Franks, C. I.
    Whately-Smith, C. R.
    Mariz, S.
    Campbell, I. W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (08) : 1775 - 1781
  • [30] Effects of Pioglitazone Add-On to Gliclazide and Metformin on Glycemic Control in Patients with Type 2 Diabetes
    Al-Azzam, Sayer I.
    AlOmari, Mousa
    Khader, Yousef S.
    AlMahasneh, Fatimah A.
    Muflih, Suhaib M.
    Altawalbeh, Shoroq
    ENDOCRINE RESEARCH, 2012, 37 (01) : 7 - 11